1182 related articles for article (PubMed ID: 11286472)
41. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection.
Tsuchiyama J; Yoshino T; Mori M; Kondoh E; Oka T; Akagi T; Hiraki A; Nakayama H; Shibuya A; Ma Y; Kawabata T; Okada S; Harada M
Blood; 1998 Aug; 92(4):1374-83. PubMed ID: 9694726
[TBL] [Abstract][Full Text] [Related]
42. Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas.
Ramakrishnan R; Donahue H; Garcia D; Tan J; Shimizu N; Rice AP; Ling PD
PLoS One; 2011; 6(11):e27271. PubMed ID: 22102884
[TBL] [Abstract][Full Text] [Related]
43. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma.
Ryan JL; Fan H; Glaser SL; Schichman SA; Raab-Traub N; Gulley ML
J Mol Diagn; 2004 Nov; 6(4):378-85. PubMed ID: 15507678
[TBL] [Abstract][Full Text] [Related]
44. Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas.
Luo B; Wang Y; Wang XF; Liang H; Yan LP; Huang BH; Zhao P
World J Gastroenterol; 2005 Feb; 11(5):629-33. PubMed ID: 15655811
[TBL] [Abstract][Full Text] [Related]
45. Expression of Epstein-Barr virus in cutaneous T-cell lymphoma including mycosis fungoides.
Shimakage M; Sasagawa T; Kawahara K; Yutsudo M; Kusuoka H; Kozuka T
Int J Cancer; 2001 Apr; 92(2):226-31. PubMed ID: 11291050
[TBL] [Abstract][Full Text] [Related]
46. No significant association of Epstein-Barr virus infection with invasive breast carcinoma.
Chu PG; Chang KL; Chen YY; Chen WG; Weiss LM
Am J Pathol; 2001 Aug; 159(2):571-8. PubMed ID: 11485915
[TBL] [Abstract][Full Text] [Related]
47. Epstein-Barr virus is localized in the tumour cells of nasal lymphomas of NK, T or B cell type.
Tao Q; Ho FC; Loke SL; Srivastava G
Int J Cancer; 1995 Jan; 60(3):315-20. PubMed ID: 7829236
[TBL] [Abstract][Full Text] [Related]
48. Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL.
Kanemitsu N; Isobe Y; Masuda A; Momose S; Higashi M; Tamaru J; Sugimoto K; Komatsu N
Clin Cancer Res; 2012 Apr; 18(8):2164-72. PubMed ID: 22371452
[TBL] [Abstract][Full Text] [Related]
49. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells.
Cuomo L; Trivedi P; de Grazia U; Calogero A; D'Onofrio M; Yang W; Frati L; Faggioni A; Rymo L; Ragona G
J Med Virol; 1998 Jul; 55(3):219-26. PubMed ID: 9624610
[TBL] [Abstract][Full Text] [Related]
50. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico.
Elenitoba-Johnson KS; Zarate-Osorno A; Meneses A; Krenacs L; Kingma DW; Raffeld M; Jaffe ES
Mod Pathol; 1998 Aug; 11(8):754-61. PubMed ID: 9720504
[TBL] [Abstract][Full Text] [Related]
51. Characteristics of Epstein-Barr virus associated childhood non-Hodgkin's lymphoma in the Republic of Korea.
Kim D; Ko Y; Suh Y; Koo H; Huh J; Lee W
Virchows Arch; 2005 Sep; 447(3):593-6. PubMed ID: 15991005
[TBL] [Abstract][Full Text] [Related]
52. High frequency of EBV association and 30-bp deletion in the LMP-1 gene in CD56 lymphomas of the upper aerodigestive tract.
Tai YC; Kim LH; Peh SC
Pathol Int; 2004 Mar; 54(3):158-66. PubMed ID: 14989738
[TBL] [Abstract][Full Text] [Related]
53. Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter.
Jiménez-Ramírez C; Brooks AJ; Forshell LP; Yakimchuk K; Zhao B; Fulgham TZ; Sample CE
J Virol; 2006 Nov; 80(22):11200-8. PubMed ID: 16956945
[TBL] [Abstract][Full Text] [Related]
54. Epstein-Barr virus (EBV) replicative gene expression in tumour cells of AIDS-related non-Hodgkin's lymphoma in relation to CD4 cell number and antibody titres to EBV.
Brousset P; Drouet E; Schlaifer D; Icart J; Payen C; Meggetto F; Marchou B; Massip P; Delsol G
AIDS; 1994 May; 8(5):583-90. PubMed ID: 7914731
[TBL] [Abstract][Full Text] [Related]
55. DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines.
Sauder C; Haiss P; Grässer FA; Zimber-Strobl U; Mueller-Lantzsch N
J Gen Virol; 1994 Nov; 75 ( Pt 11)():3067-79. PubMed ID: 7964616
[TBL] [Abstract][Full Text] [Related]
56. A Genome-Wide Epstein-Barr Virus Polyadenylation Map and Its Antisense RNA to EBNA.
Majerciak V; Yang W; Zheng J; Zhu J; Zheng ZM
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355690
[TBL] [Abstract][Full Text] [Related]
57. BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells.
Wang H; Zhao Y; Zeng L; Tang M; El-Deeb A; Li JJ; Cao Y
Anticancer Res; 2004; 24(1):67-74. PubMed ID: 15015577
[TBL] [Abstract][Full Text] [Related]
58. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders.
Iwatsuki K; Satoh M; Yamamoto T; Oono T; Morizane S; Ohtsuka M; Xu ZG; Suzuki D; Tsuji K
Arch Dermatol; 2006 May; 142(5):587-95. PubMed ID: 16702496
[TBL] [Abstract][Full Text] [Related]
59. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
60. Synergy between human immunodeficiency virus type 1 and Epstein-Barr virus in T lymphoblastoid cell lines.
Zhang RD; Guan M; Park Y; Tawadros R; Yang JY; Gold B; Wu B; Henderson EE
AIDS Res Hum Retroviruses; 1997 Jan; 13(2):161-71. PubMed ID: 9007201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
